Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs.

BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts.

Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets

BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Ginkgo will build a platform driven by its Reconfigurable Automation Carts (RACs) technology to enable EMSL's open-ended exploration of bioconomy-relevant microbes

BOSTON, July 30, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory (PNNL), a leading U.S. Department of Energy Office of Science user facility, has selected Ginkgo Automation to deliver a state-of-the-art automated anaerobic phenotyping platform at its Richland, Washington campus. This purchase marks a significant step in EMSL's mission to advance fundamental biological research supporting U.S. energy production, ensuring leadership in the bioeconomy, and establishing critical materials supply-chain resilience.

Ginkgo Bioworks launches cost-effective, high-throughput ADME profiling service to accelerate small molecule drug discovery with model-ready datasets

BOSTON, July 17, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of a powerful new capability at Ginkgo Datapoints: high-throughput, low-cost ADME (Absorption, Distribution, Metabolism, and Excretion) profiling, enabled by Ginkgo's proprietary RAC automation. This new service aims to beat or match the price of Chinese or other international vendors, with all work performed in the United States.

BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation.

Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target

Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems

BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

YOKNE'AM ILLIT, Israel and BOSTON, April 30, 2025 /PRNewswire/ -- Phytolon, a biotech-foodtech startup that offers natural food colors via fermentation of baker's yeast, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of the second development milestone of their multi-product collaboration to produce natural food colors and the resulting distribution of an equity milestone to Ginkgo.

Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025

BOSTON, April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET.

BOSTON, April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. This advanced modular laboratory automation platform will be deployed at Aura Genetics' new 22,000-square-foot high-throughput facility at the UPS Healthcare Labport, located at the end of the runway at the Louisville, KY airport.The RAC system, combined with Ginkgo Automation's orchestration software and real-time error resolution services, aims to enable Aura Genetics to efficiently scale and streamline diagnostic testing workflows. Supported by Ginkgo's team of automation engineers and scientists, Aura Genetics expects to be able to process tens of thousands of samples daily, ensuring seamless integration and rapid, high-quality results."We are proud that Aura Genetics has chosen Ginkgo Automation's RAC system for their new state-of-the-art facility," said Will Serber, General Manager of Ginkgo Automation. "Our modular automation solutions are built to scale with our customers' needs. By deploying this technology, Aura Genetics is setting a new benchmark for efficiency and innovation in laboratory testing, and we look forward to supporting their continued growth."Anthony Nuccio, COO of Aura Genetics, added, "Partnering with Ginkgo Automation marks a significant step forward for Aura Genetics. The sophisticated automation capabilities provided by Ginkgo will allow us to scale our operations efficiently, accelerate turnaround times, and bring innovative lab testing solutions to market more rapidly."The agreement includes extensive collaborative support, including joint protocol development, biovalidation, and dedicated on-demand technical support, reinforcing both companies' commitment to quality, innovation, and scientific rigor.About Ginkgo BioworksGinkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.About Aura GeneticsAura Genetics is a pioneering, CLIA Certified and CAP Accredited high-complexity diagnostic laboratory redefining modern diagnostic testing by delivering same-morning results through it's runway-adjacent lab, and joint project with UPS Healthcare. Aura Genetics empowers healthcare providers with actionable 'Lab results at the speed of FLIGHT,' enhancing diagnostics and personalized medicine outcomes.

Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems

BOSTON, April 10, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences, US Pharmacopeia (USP), On Demand Pharmaceuticals, and Isolere Bio by Donaldson. This two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems.

Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target

Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023

BOSTON, Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

BOSTON, Feb. 21, 2025 /PRNewswire/ -- Volta Labs, a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow.

"I like the Apps and the App Store concept on Callisto. It allows us to keep our operating costs low and access multiple sequencing technologies and chemistries on the same platform," said Alex Plocik, Senior Director of Genomics at Ginkgo Bioworks. "In our short-read sequencing workflow, we often pool thousands of individual samples into tens of sample pools for bead clean ups with varying batch size from day to day. The Callisto system is perfect for this use case while providing a complete walk away experience." 

International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness

BOSTON, Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European Commission.

Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025

BOSTON, Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024, on Tuesday, February 25, 2025, beginning at 5:30 p.m. ET.

Evolution of Ferment conference to kick off Summer 2025

BOSTON, Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC

BOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bioenergy Research Center at the University of Wisconsin–Madison. This new system is designed to support the diverse needs of multiple investigators and research teams simultaneously, enabling GLBRC scientists to more efficiently discover and optimize synthesis of biofuels and bioproducts from plant biomass.

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics

BOSTON, Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.

BOSTON, Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. PT (1:30 p.m. ET).

Further details, a webcast link, and a replay of the presentation will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders

BOSTON, Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program. Ginkgo is eligible to receive up to $9.4 million for its work across the program.

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions

Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck 

BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.